All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Mounjaro Results After 2 Years: What to Expect

What do Mounjaro results after 2 years look like? SURPASS and SURMOUNT long-term data, sustained A1C and weight outcomes, and practical guidance for...

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Mounjaro Results After 2 Years: What to Expect custom 2026 header image for GLP-1 Weight Loss
Custom header image for Mounjaro Results After 2 Years: What to Expect, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Mounjaro Results After 2 Years: What to Expect

What do Mounjaro results after 2 years look like? SURPASS and SURMOUNT long-term data, sustained A1C and weight outcomes, and practical guidance for...

Short answer

What do Mounjaro results after 2 years look like? SURPASS and SURMOUNT long-term data, sustained A1C and weight outcomes, and practical guidance for...

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

See your GLP-1 options in about 2 minutes. Free and private. See my options →

What do Mounjaro results after 2 years look like? SURPASS and SURMOUNT long-term data, sustained A1C and weight outcomes, and practical guidance for continued treatment.

Mounjaro (tirzepatide) has delivered some of the most impressive outcomes in both diabetes and weight management, and patients who have been on treatment for 2 years are seeing lasting benefits. Here is a thorough look at what Mounjaro results after 2 years actually mean for your health.

Two-Year Clinical Outcomes

Data from the SURPASS trials (diabetes focus) and SURMOUNT trials (obesity focus) inform our understanding of 2-year Mounjaro results:

  • SURPASS-4 (up to 104 weeks): This open-label trial compared Mounjaro to insulin glargine in patients with type 2 diabetes. At 52 weeks, Mounjaro 15 mg produced A1C reductions of 2.58% and weight loss of 11.7 kg (25.8 lbs). Extended observation suggests these benefits are maintained or slightly improve through 2 years .
  • SURMOUNT-4[1] (88 weeks): Continued tirzepatide treatment produced approximately 26% total body weight loss. For a 240-pound patient starting, that's roughly 62 pounds .

The combined diabetes and weight management benefits make Mounjaro uniquely valuable for patients dealing with both conditions simultaneously.

Two-Year Timeline for Mounjaro Patients

  • Months 1 to 3 (2.5 mg to 7.5 mg): Titration. Weight loss of 5 to 12 pounds. A1C begins dropping rapidly, often 1.0% or more in the first 3 months. GI side effects are most pronounced but usually manageable.
  • Months 4 to 8 (10 mg to 15 mg): Peak efficacy phase. Cumulative weight loss of 18 to 35 pounds. A1C may drop 2.0% to 2.5% from baseline. Many patients reduce or stop other diabetes medications.
  • Months 9 to 14: Continued progress at a moderating pace. Cumulative weight loss of 30 to 50 pounds. Metabolic health markers stabilize at improved levels. Side effects are generally well-managed.
  • Months 15 to 18: Most patients reach their weight plateau. Cumulative loss of 40 to 55 pounds. A1C remains well-controlled.
  • Months 19 to 24: Sustained maintenance. Weight and A1C remain stable. Total sustained weight loss of 25 to 60+ pounds. Total A1C reduction of 2.0% to 2.6% maintained.

Diabetes Management at Two Years

For patients taking Mounjaro for type 2 diabetes, the 2-year outcomes are particularly noteworthy:

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Mounjaro Results After 2 Years: What to Expect
  • A1C below 7.0%: Approximately 80% to 90% of patients on Mounjaro 15 mg achieve this standard target at 2 years .
  • A1C below 5.7% (normoglycemia): Between 30% and 50% of patients achieve normal blood sugar levels, a remarkable outcome for a diabetes medication.
  • Insulin discontinuation: Many patients starting on insulin are able to stop insulin entirely under provider supervision, particularly those with less advanced disease.
  • Reduced medication burden: Beyond insulin, patients often reduce metformin, sulfonylureas, and SGLT2 inhibitors as their metabolic health improves.
  • Sustained kidney protection: Weight loss and improved blood sugar together reduce the progression of diabetic nephropathy over 2 years .

What to Watch for in Year Two

  • Hypoglycemia awareness: As blood sugar control improves, patients on insulin or sulfonylureas face increased hypoglycemia risk. These medications should be proactively reduced under medical guidance.
  • Nutritional adequacy: Two years of reduced appetite can lead to cumulative nutritional gaps. Annual screening for B12, vitamin D, iron, calcium, and folate is important.
  • Bone health: Significant weight loss can affect bone density. Consider a DEXA scan at the 2-year mark, especially for postmenopausal women.
  • Diabetic retinopathy monitoring: Rapid blood sugar improvement can transiently worsen diabetic retinopathy. Annual eye exams are important, particularly in the first 2 years of treatment .
  • Gallbladder health: Report any right-sided abdominal pain. The risk of gallstones is improved with weight loss exceeding 5% of body weight.

Strategies for Sustained Two-Year Success

  • Partner with your endocrinologist or PCP: At 2 years, thorough medication review is important. Your entire diabetes regimen may look different from when you started.
  • Build a maintenance-focused exercise routine: Shift from "losing" to "building." Resistance training supports muscle mass, insulin sensitivity, and bone health.
  • Eat intentionally: With sustained appetite suppression, make every meal count. Focus on protein (30+ grams per meal), colorful vegetables, and whole grains.
  • Plan financially: Budget for continued treatment. Explore insurance improvement, manufacturer coupons, or compounded semaglutide alternatives if cost becomes prohibitive $1,000-$1,200/mo (brand).
  • Celebrate your progress: Two years of improved health is a genuine achievement. Acknowledge the work you have put in.

Frequently Asked Questions

Can I take Mounjaro for more than 2 years?

Yes. Mounjaro is approved for chronic long-term use in type 2 diabetes with no specified maximum duration. Ongoing treatment maintains both blood sugar control and weight management benefits . For a complete cost breakdown, see our best tirzepatide compounding pharmacies.

Is Mounjaro or Zepbound better for long-term use?

They contain the same medication (tirzepatide). The choice depends on your primary indication: Mounjaro for diabetes, Zepbound for obesity. Insurance coverage often determines which is more practical for a given patient.

What if my diabetes goes into remission on Mounjaro?

Diabetes remission (A1C below 6.5% without diabetes medication other than Mounjaro) is achievable for some patients. But stopping Mounjaro typically leads to blood sugar and weight relapse. Most providers recommend continuing treatment to maintain remission .

Are there newer alternatives I should consider at 2 years?

The GLP-1 field is evolving rapidly. Oral semaglutide, retatrutide (a triple agonist), and survodutide are in various stages of development. Stay informed through your provider about whether emerging options might offer advantages for your specific situation.

What labs should I get at 2 years?

Thorough panel: A1C, fasting glucose, fasting insulin, C-peptide, complete lipid panel, liver enzymes, kidney function (creatinine, eGFR, UACR), thyroid panel, CBC, B12, vitamin D, iron studies, and calcium. DEXA scan for body composition and bone density assessment.

Medical References

  1. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]

Continue Thriving on Mounjaro

Two years of Mounjaro treatment represents a significant investment in your metabolic health. The clinical data confirms that these benefits are real, substantial, and sustained with continued use. FormBlends offers ongoing clinical support to help you get the most from your treatment.

Connect with a licensed provider to review your 2-year Mounjaro results and plan ahead.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Mounjaro evidence source
Official source
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Zepbound evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Mounjaro Results After 2 Years: What to Expect, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Mounjaro Results After 2 Years: What to Expect research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

What do Mounjaro results after 2 years look like? SURPASS and SURMOUNT long-term data, sustained A1C and weight outcomes, and practical guidance for continued treatment. "Mounjaro Results After 2 Years: What to Expect" is most useful when you treat it as decision prep, not a shortcut. The page is built around patient education and clinical context, with the highest-value checks sitting around tirzepatide. Because this article has 7 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. If the answer affects treatment, cost, pharmacy choice, or dosing, bring the specifics to a licensed clinician before acting.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Mounjaro Results After 2 Years

For this glp-1 weight loss page, the 2026 refresh focuses on semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, mounjaro so the article stays close to the question behind "Mounjaro Results After 2 Years".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Mounjaro Results After 2 Years from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Mounjaro Results After 2 Years custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Mounjaro Results After 2 Years, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Mounjaro Results After 2 Years, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.